The Salford Lung Study in Chronic Obstructive Pulmonary Disease (SLS COPD) compared the initiation of once-daily fluticasone furoate/vilanterol 100/25μg (FF/VI) treatment versus continuation of usual care (UC). The annual rate of moderate or severe exacerbations was significantly lower for patients initiated on FF/VI compared with UC (Vestbo, NEJM 2016). We conducted a follow-up study to compare the experiences of patients completing SLS COPD, by exacerbation rate and randomized treatment.
http://ift.tt/2zd0Gw1
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου